The EU’s “hospital exemption” rule permits the manufacture and use of CAR-T therapy in academic centers, with member state regulatory oversight. This has been proposed as an alternative to the commercial model for CAR-T development, with global clinical trials and centralized regulatory approval, manufacturing and pharmacovigilance.